help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 50, No. 1 179-181
doi:10.1210/jcem-50-1-179
Copyright © 1980 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by CASPER, R. F.
Right arrow Articles by YEN, S. S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by CASPER, R. F.
Right arrow Articles by YEN, S. S. C.

Gonadotropin-Estradiol Responses to a Superactive Luteinizing Hormone-Releasing Hormone Agonist in Women*

ROBERT F. CASPER{dagger}, KATHARINE L. SHEEHAN{ddagger} and SAMUEL S. C. YEN§

Department of Reproductive Medicine, School of Medicine (T-002), University of California, San Diego, La Jolla, California 92093

ABSTRACT. After the sc administration of 1, 10, and 50 µg of the LRF agonist [D-Trp6,Pro,9,NEt]LRF, dose-dependent increments in circulating levels of LH, FSH, and estradiol were observed which were 2- to 3-fold greater in the late than in the early follicular phase. The 10-µg dose of LRF agonist appears to induce a maximal acute gonadotropin-estradiol response. Both 10- and 50-µdoses of the agonist elicited gonadotropin increments which were several times greater than that seen during the midcycle surge. The only difference between the two doses was the more sustained action on gonadotropin release of the latter. It is estimated that this superactive LRF agonist is approximately 140 times more potent than the decapeptide LRF. These observations provide information useful in the application of this LRF agonist for clinical studies. (J Clin Endocrinol Metab 50: 179, 1980)

* This work was supported by NIH Grant HD-12303 and Rockefeller Foundation Grant RF-75029.

{dagger} Research Fellow in Reproductive Endocrinology, supported by the Medical Research Council of Canada.

{ddagger} Research Fellow in Reproductive Endocrinology.

§ To whom all correspondence and requests for reprints should be addressed.

Received April 12, 1979.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society